La cadena de opciones muestra datos clave de las opciones de acciones de BioLine Rx a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para BioLine Rx..

BioLine Rx (NASDAQ:BLRX) Bolsa, Cadena de Opciones

BioLine Rx

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLineRx Ltd. - American Depositary Shares

BioLine Rx Ltd

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) with a Buy and maintains $21 price target.

News

Price Target

Reiteration

Analyst Ratings

BLRX

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle -&nbsp;
- Data from proof-of-concept&nbsp;study shows that motixafortide was safe and well tolerated -
- Oral presentation at ASH 2024 on Saturday, December 7, 2024 in San Diego, California -
TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- <a href="https://biolinerx.com/">BioLineRx&nbsp;Ltd.</a>&nbsp;(NASDAQ:&nbsp;BLRX) (TASE:&nbsp;BLRX),&nbsp;a commercial&nbsp;stage&nbsp;biopharmaceutical&nbsp;company pursuing&nbsp;life-changing&nbsp;therapies&nbsp;in&nbsp;oncology&nbsp;and rare diseases,&nbsp;today&nbsp;announced&nbsp;that an abstract including the initial results from a Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD) was accepted for oral presentation&nbsp;at the 66th&nbsp;American Society of Hematology (ASH) Annual Meeting &amp; Exposition taking place&nbsp;December 7-10, 2024 in San Diego, California. The proof-of-concept study, conducted in collaboration with Washington University School of Medicine in St. Louis, is exploring alternative HSC mobilization strategies that could significantly improve the treatment journey of patients with sickle cell disease seeking gene therapy. &nbsp;&nbsp;

Biotech

General

BioLineRx Announces Oral Presentation On Data From Phase 1 Clinical Trial Evaluating Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapies In Sickle Cell Disease At ASH 2024

BioLineRx Announces USPTO Allowance Of New Composition Of Matter Patent Covering Composition Of Motixafortide

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock rose 89.7% to $0.72 during Friday's after-market session. The market value of their outstanding shares is at $122.8 million. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock rose 5.75% to $0.69. The market value of their outstanding shares is at $61.2 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock rose 5.4% to $0.39. The company's market cap stands at $36.7 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares increased by 5.02% to $0.26. The company's market cap stands at $14.4 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 4.99% to $0.54. The company's market cap stands at $2.3 million. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) shares moved upwards by 4.98% to $12.84. The market value of their outstanding shares is at $771.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 8.4% to $0.95 during Friday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 7.79% to $3.79. The market value of their outstanding shares is at $5.0 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares declined by 7.56% to $0.72. The market value of their outstanding shares is at $7.6 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 7.14% to $0.91. The company's market cap stands at $9.2 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares fell 6.88% to $0.45. The company's market cap stands at $36.2 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock fell 6.36% to $0.17. The company's market cap stands at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACON

AKAN

ALLK

CARA

DWTX

IMNM

NIVF

PTIX

TVGN

UNCY

12 Health Care Stocks Moving In Friday's After-Market Session

Shares of Arcadium Lithium plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NASDAQ">ALTM</a>) rose sharply in today's pre-market trading after the company confirmed non-binding acquisition <a href="https://www.benzinga.com/quote/ALTM/analyst-ratings">approach by Rio Tinto</a>.
Arcadium Lithium shares jumped 27.8% to $3.94 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) rose 54.5% to $0.1735 in pre-market trading after dipping 17% on Friday.</li>
<li>TDH Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETZ#NASDAQ">PETZ</a>) rose 36.2% to $1.84 in pre-market trading after jumping 13% on Friday.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) gained 16.8% to $1.95 in pre-market trading after declining 5% on Friday.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) shares gained 13.3% to $14.04 in pre-market trading after jumping around 35% on Friday.</li>
<li>Garden Stage Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIW#NASDAQ">GSIW</a>) shares rose 13.1% to $2.16 in pre-market trading after gaining around 3% on Friday.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) shares surged 12.6% to $1.25 in pre-market trading after dipping 17% on Friday.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) shares jumped 11% to $4.13 in pre-market trading after gaining 17% on Friday.</li>
<li>The Duckhorn Portfolio, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAPA#NYSE">NAPA</a>) shares gained 11% to $6.00 in pre-market trading ahead of quarterly earnings.</li>
<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) gained 9.5% to $0.5035 in pre-market trading after dipping around 12% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Trevena, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares dipped 39% to $2.81 in pre-market trading after the company announced it received a Nasdaq delisting notification.</li>
<li>Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) fell 22.2% to $1.47 in today's pre-market trading. Beneficient shares jumped around 59% on Friday after the company announced its subsidiary, Beneficient Company Holdings, consummated a previously announced transaction pursuant to which approximately $126 million of its preferred equity was redesignated as non-redeemable.</li>
<li>Mynaric AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) shares fell 18.7% to $1.26 in pre-market trading after gaining 4% on Friday.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) fell 18.4% to $1.64 in pre-market trading after declining 21% on Friday.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) declined 17.2% to $0.2330 in pre-market trading after dipping around 24% on Friday.</li>
<li>Vicinity Motor Corp.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) shares declined 17.3% to $0.1448 in pre-market trading after gaining around 23% on Friday.</li>
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) fell 15.8% to $1.75 in pre-market trading after declining 8% on Friday.</li>
<li>Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares fell 15.8% to $12.47 in pre-market trading after jumping 387% on Friday.</li>
<li>Stepan Company  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCL#NYSE">SCL</a>) shares fell 6.5% to $72.29.</li>
<li>Fortuna Mining Corp. NYSE: FSM) shares declined 5.3% to $4.62 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41196046/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yiel">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ALTM

BENF

CETX

CHSN

CTNT

EFSH

FAAS

GSIW

LGMK

MYNA

NAPA

PETZ

TIGR

TRVN

Why Arcadium Lithium Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket

Patient&nbsp;survey&nbsp;currently&nbsp;underway in&nbsp;partnership&nbsp;with&nbsp;the&nbsp;HealthTree Foundation; data expected in Q1 2025
TEL AVIV, Israel and WALTHAM, Mass., Sept. 17, 2024 /PRNewswire/ -- <a href="https://biolinerx.com/">BioLineRx&nbsp;Ltd.</a>&nbsp;(NASDAQ:&nbsp;BLRX) (TASE:&nbsp;BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the launch of <a href="https://www.mobilizationmatters.com/">Mobilization&nbsp;Matters</a>,&nbsp;a&nbsp;digital&nbsp;resource for&nbsp;people with multiple myeloma who are preparing for stem cell collection for an autologous stem cell transplant. Launched on Apheresis Awareness Day, this platform offers patient stories, educational resources, and more to support those undergoing this critical phase of treatment.

BioLineRx Launches 'Mobilization Matters', A Digital Resource For People With Multiple Myeloma Preparing For Stem Cell Collection; Patient Survey Currently Underway In Partnership With The HealthTree Foundation; Data Expected In Q1 2025

Jones Trading analyst Justin Walsh initiates coverage on BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) with a Buy rating and announces Price Target of $2.

Initiation

Jones Trading Initiates Coverage On BioLine Rx with Buy Rating, Announces Price Target of $2

WIIM

BioLineRx shares are trading lower. The company reported Q2 financial results.

Earnings

Guidance

Health Care

As Of June 30, 2024, BioLineRx Had Cash, Cash Equivalents, And Short-term Bank Deposits Of $40.1M Expected To Be Sufficient To Fund Operations, As Currently Planned, Into 2025

BioLine Rx Q2 2024 GAAP EPS $0.00 Beats $(0.14) Estimate, Sales $5.393M Beat $3.930M Estimate

BioLineRx Announces Multi-Center Phase 1 Trial Sponsored By St. Jude Children's Research Hospital To Evaluate Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications In Sickle Cell Disease

BioLineRx shares are trading higher. The company reported Q1 financial results.

The company says this amount does not include $6.0 million in gross proceeds received from a registered direct offering and a $20.0 million&nbsp;drawdown of the second tranche from the existing loan agreement with BlackRock, which were both completed in April 2024.

BioLineRx Says Cash, Cash Equivalents, And Short-Term Bank Deposits Of $28.2M Will Be Sufficient To Fund Operations, As Currently Planned, Into 2025

BioLine Rx Q1 2024 GAAP EPS $(0.00) May Not Be Comparable To $(0.29) Estimate, Sales $6.855M May Not Be Comparable To $340.000K Estimate

<ul>
<li>New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients treated&nbsp;&nbsp;</li>
<li>7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed;&nbsp;10 of 11 patients&nbsp;experienced disease control&nbsp;&nbsp;</li>
<li>Poster&nbsp;Presentation on&nbsp;Saturday, June 1, 2024&nbsp;in&nbsp;Chicago, Illinois&nbsp;</li>
</ul>

BioLineRx Discloses Abstract On Pilot Study Data From Phase 2 Combination Clinical Trial Evaluating Motixafortide In First-Line Pancreatic Cancer At American Society of Clinical Oncology 2024 Annual Meeting

BioLineRx To Present Poster On Economic Model Data For APHEXDA Today At ISPOR 2024

BioLineRx Announces Poster Presentation On Apheresis Center Efficiency And CXCR4 Antagonists Including APHEXDA At ASFA 2024 Annual Meeting Apr. 17-19

Warning: BLRX is at high risk of performing badly

Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BioLineRx Ltd has announced promising results from a Phase 1 clinical trial evaluating ...

BioLineRx's Motixafortide Shows Promise in Sickle Cell Trials

Small Cap

Press Releases

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Comments

BioLine Rx

BioLine Rx (BLRX) Opciones

BioLine Rx (NASDAQ:BLRX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL